https://www.selleckchem.com/pr....oducts/oss-128167.ht
Radiolabeled peptides play a central role in nuclear medicine as radiotheranostics for targeted imaging and therapy of cancer. We have recently proposed the use of metabolically stabilized GRPR antagonist BBN2 for radiolabeling with F and Ga and subsequent PET imaging of GRPRs in prostate cancer. The present work studied the impact of Sc- and Ga-labeled DOTA complexes attached to GRPR antagonist BBN2 on the in vitro GRPR binding affinity, and their biodistribution and tumor uptake profiles in MCF7 breast and PC3 prostate cancer model
Aimer
Commentaire
Partagez
